Xing X, Zhang X, Wang K, Wang Z, Feng Y, Li X, Hua Y, Zhang L, Dong X.
Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Alzheimers Res Ther. 2025 Jan 8;17(1):15.
PubMed.
Comments
No Available Comments
Make a Comment
To make a comment you must login or register.